Revumenib
Small Molecule
Overview
Revumenib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL4650827).
Patent & exclusivity (US)
Per the FDA Orange Book (3 approved US products), the latest listed US patent on Revumenib expires 18 Dec 2042 and exclusivity 15 Nov 2031. Generic API sourcing typically opens up once these lapse.
Ready to Accelerate Your
Discovery Workflow?
Find, vet, and source drug-manufacturing partners faster — with FDA compliance screening built in. Start free for 14 days.